環遊世界, 傳染病學會美國的準則被用於由醫生, 政府和醫療保險公司確定病人的萊姆病的診斷和治療. These guidelines have been controversial. Much of the disagreement centers on how to treat patients who experience debilitating and long lasting symptoms (known as chronic Lyme disease) when the disease is caught late. 該 2006 IDSA guidelines were challenged by then Connecticut Attorney General Richard Blumenthal, but after review by a selected panel of experts in 2010, none of the 69 original recommendations were changed. The guidelines continue to set doctor against doctor and scientist against scientist. The real losers in the Lyme debate are the patients who just get sicker while the most important questions of all — Why can’t they get better? and What can we do to help them? — remain unanswered.
Times may be changing. Innovative research is presenting clues to Lyme persistence. Efforts have begun to share knowledge with international doctors and scientists concerned about the dramatic growth of Lyme and tick-borne illnesses in Asia, 歐洲, 南美洲, Australia and Canada. Ecologists have published studies on the emergence and spread of the disease. 進一步, the CDC reported an increase in 2012 的 1500% in annual incidence in the US alone, raising Lyme disease visibility globally and supporting the need for a comprehensive prevention campaign. It is troubling to imagine what the 300,000 estimate might exclude given the arguments of poor surveillance for Lyme in less endemic states and the fact that doctors rely on diagnostic tests which experts globally agree are just not sensitive enough. Even with the surveillance methods used historically, Lyme disease tripled between 1992 和 2009.
How can we move forward? 我問醫生. Paul Auwaerter from the Infectious Diseases Society of America (IDSA), 參議員理查德·布盧門撒爾, Senator Kirsten Gillibrand and Congressman Chris Smith to join in the worldwide discussion in Part 12 我的世界系列, “蜱”.
The CDC’s astonishing increase in 2012 的 1500% in the annual incidence of Lyme disease to 300,000 raises the visibility of Lyme disease to doctors, patients and health insurance providers. Do you believe the current IDSA guidelines cover all the 300,000 cases?
博士. Auwaerter: This study gives an estimate of annual cases. 歷史, 任何 “reported” infection to the CDC has been typically only 10% of actual, so this study comports with those for venereal diseases, food borne infections, 等. 這說, Lyme disease has increased in numbers over the past decade and is slowly spreading regionally from initial focus in Upper Midwest and coastal/riparian New England. Regardless of the number of cases, the current IDSA guidelines provide the best scientific, evidence-based medical practices for the treatment of Lyme disease including early and late forms.
Congressman Smith: Not an increase, just the real number validated. We have known for some time that only 10 percent of Lyme disease cases have been reported and the new CDC numbers confirm this fact. The real number of Lyme disease patients was misrepresented for so long, and so too was the reality of “chronic Lyme.” It’s why the disease is known as the “great pretender.”
We haven’t seen any efforts on the part of government agencies to review guidelines or revisit contrarian research denying chronic Lyme disease but we have again asked CDC to update its guidelines to assist individuals suffering from Lyme.
Senator Gillibrand: Lyme and tick-borne diseases are a pervasive and pernicious concern to our nation’s public health, and it is critical that we have accurate diagnosis and treatment guidelines. 今年早些時候，, I sent a letter to the Emergency Care Research Institute (ECRI) urging for transparency in the methodology used to review the Infectious Diseases Society of America’s (IDSA) Lyme disease guidelines. It is a matter of public health that these guidelines be thoroughly reviewed as is required by the National Guidelines Clearinghouse.
Senator Blumenthal: Lyme is an insidious, devastating disease that is difficult to both diagnose and treat. It has spread over the past decade, with alarming rates of infection in Connecticut causing life-long harm to children and adults. I have long been an advocate for a comprehensive national strategy to combat and conquer Lyme, which is why I have introduced the Lyme and Tick-Borne Disease Prevention, 教育, and Research Act to provide additional resources to support, evaluate, and advance diagnoses and treatment as well as prevention. The statistics from CDC highlight the need for more research in this area.
博士. Auwaerter: Do the guidelines allow for antibiotic treatment in the event of typical Lyme disease symptoms without either of the EM rash or positive Western blot test?
I am not sure what you mean, but Lyme disease should be treated if someone has acute symptoms and the typical rash. In patients who are acutely ill and have fever, this is non-specific, but we often treat empirically with doxycycline for tick-borne infections if patients have a risk of acquisition. Your answer for patients with long-term symptoms (not acute) would be no, we need to see laboratory evidence of infection in patients with problems that could be attributable to Lyme disease.
博士. Auwaerter: If victims do not have chronic Lyme how do you explain the ongoing symptoms in patients who remain ill long after they have been treated?
Chronic Lyme disease is an indistinct term. I prefer to use terms such as late Lyme disease (for example with an active infection needing antibiotics such as a swollen knee arthritis due to B. 螺旋體) or post-treatment Lyme disease syndrome for those symptoms that persist after antibiotics that often resemble fibromyalgia, or chronic fatigue. The post-infectious syndrome cause is not known and hence why we use the term syndrome. It is more common in women and in those who have had untreated infection for longer periods of time.
博士. Auwaerter: There are a number of newer studies (animal models and human models) that indicate the Lyme bacteria can hide in protective structures from antibiotics. Can you comment on this research?
There are no high quality human studies to back up this comment. For animal models, other than occasional antibiotic treatment failure, what most of these animal studies have found is evidence by PCR methodology of DNA for B. 螺旋體 – but not cultivable, viable bacteria. The significance of this is unclear, and many bacterial and viral infections have evidence of DNA debris in both animals and humans that persist after resolution of infection.
博士. Auwaerter: What do you say to patients around the world who believe long term antibiotics for Lyme disease made them better?
Four randomized, placebo-controlled trials have failed to find that long-term antibiotics provide durable benefit of symptoms that persist after initial antibiotic therapy for Lyme disease. 事實上, about one third of placebo recipients improved, suggesting that people who have fatigue, migratory muscle and joint pains as well as disturbed sleep and brain fog do improve over time. It’s without any solid merit that advocates of long-term therapy have provided any evidence their patients do better than placebo.
博士. Auwaerter: Doctors around the world claim they are seeing more patients with co-infections. Might this be the reason why patients with Lyme disease continue to feel unwell?
Authentic co-infection is rare. 在過去 15 歲月, I have never verified a co-infection (巴貝斯, Ehrlichia, RMSF, 巴爾) that was diagnosed by so-called Lyme experts (LLMD). Co-infection, much like Lyme disease, is over diagnosed as an explanation for chronic symptoms of fatigue, un-wellness.
Given the newly acknowledged level of incidence, is it now advisable for government health agencies to delve into the possible links to Lyme disease with degenerative neurological diseases, blood bank quality and long-term persistent illness?
Senator Gillibrand: There is much more that needs to be done to support the individuals afflicted with these crippling diseases and their families. I have met with researchers and analysts from various microbiology and infectious disease programs at the National Institutes of Health (NIH) to express my support for additional research. I am also a co-sponsor of the Lyme and Tick-Borne Disease Prevention, 教育, and Research Act, which would assist patients afflicted by these diseases by creating a national advisory committee to bring together key stakeholders, support the development of improved diagnostic tools and treatments, promote education, awareness, and prevention, and improve data reporting.
Another alarming factor in the growth of these diseases is their place in our blood supply. The American Red Cross has now confirmed at least 12 deaths nationwide from the tick-borne disease Babesiosis after it was transmitted by transfused blood. We need to ensure that our donor supply is thoroughly tested and free of disease to put a stop to these infections.
Congressman Smith: We do not have a good grasp on the complexities of Lyme, much less the myriad co-infections that greatly compound and confound diagnosis and treatment. It’s certainly advisable to explore any links to other diseases that share symptoms with Lyme. There may be new technologies which can be looked into to search for such links. I have introduced bipartisan legislation, H.R. 610, to establish a Tick-Borne Disease Advisory Committee to bring together experts from across the spectrum without any agendas.
Senator Blumenthal: All appropriate avenues of research should be undertaken by scientists and medical professionals – supported by relevant government agencies. Scientists and medical professionals should make such research decisions based on facts and evidence.
300,000 new cases of Lyme disease in the US alone plus a rise in incidence in other international nations – is a significant increase in research funding called for to address the range of issues?
Senator Gillibrand: The CDC has singled out Lyme disease as the most common and fastest growing vector-borne, infectious disease in the country affecting hundreds of thousands of Americans. Given how quickly this extremely incapacitating disease is growing, we must continue to invest in research and develop treatment and therapies for these diseases.
博士. Auwaerter: I agree more research would be helpful and should be prioritized as follows:
1) Active tick epidemiology studies to understand what ticks carry in regions so MD’s may be aware of which infections to consider. This is not a well-funded arena.
2) Improved diagnostics for Lyme disease for early infections. Current testing is excellent to diagnose Lyme disease of 3-4 weeks duration.
3) Study of post-infectious fatigue syndrome to understand the basis as well as improved treatments.
4) Additional studies of long-term antibiotics would be a lower priority since studies to date have not provided a signal regarding benefit.
Congressman Smith: International collaboration to fight the spread of Lyme and tick-borne diseases needs to be pursued. Cooperation would be useful and efficacious.
Senator Blumenthal: As I have long advocated, increased Lyme research and funding are critical and urgent.
We are seeing growing problems with Lyme and tick borne diseases in countries such as Germany, 中國, 荷蘭, 奧地利, 瑞典, Finland and Norway among others. Given the global magnitude, should collaborative international funding be pursued?
Senator Blumenthal: Collaboration and increased awareness are important for understanding the global scope of this insidious, spreading disease.
Congressman Smith: Lyme disease is the most common tick borne illness in the U.S. and is also endemic in areas of Europe and Asia, and recently has been confirmed to be endemic in South America in the Amazon region. Surveillance studies have described growing problems in Australia and Canada as well. Some advocates in the U.K. have been part of an effort to foster collaboration to address Lyme disease in Europe, and frankly I would like to see more of that type of cooperation here in the United States.
Senator Gillibrand: The difficult economic climate we face has put great strains on federal funding to pursue public health research. We should certainly work collaboratively to tackle this important issue.
Photos are courtesy of CDC, 懷特曼沙龍, Lyme Disease Action and the Richard Ostfeld Laboratory.
欲了解更多蜱文章: 點擊這裡
在全球搜索教育, 和我一樣，全球知名的思想領袖，包括邁克爾·巴伯爵士 (英國), 博士. 邁克爾座 (美國), 博士. 萊昂特司特因 (美國), 克萊克里斯坦森教授 (美國), 博士. 琳達·達林 - 哈蒙德 (美國), 博士. 馬達夫恰範 (印度), 邁克爾·富蘭教授 (加拿大), 霍華德·加德納教授 (美國), 安迪·哈格里夫斯教授 (美國), 伊馮娜赫爾曼教授 (荷蘭), 克里斯汀Helstad教授 (挪威), 讓·亨德里克森 (美國), 玫瑰Hipkins教授 (新西蘭), 科妮莉亞Hoogland教授 (加拿大), 這位傑夫·約翰遜 (加拿大), 太太. 尚塔爾考夫曼 (比利時), 博士. Eija Kauppinen (芬蘭), 國務秘書塔皮奧Kosunen (芬蘭), 多米尼克·拉方丹教授 (比利時), 休·勞德教授 (英國), 本·萊文教授 (加拿大), 主肯麥克唐納 (英國), 巴里McGaw教授 (澳大利亞), 希夫納達爾 (印度), Ř教授. 納塔拉詹 (印度), 博士. 吳PAK (新加坡), 博士. 丹尼斯教皇 (美國), 斯瑞達拉賈戈帕蘭 (印度), 博士. 黛安·拉維奇 (美國), 理查德·威爾遜·賴利 (美國), 肯·羅賓遜爵士 (英國), 帕西SAHLBERG教授 (芬蘭), 押尾佐藤教授 (日本), 安德烈亞斯·施萊歇 (PISA, 經合組織), 博士. 安東尼·塞爾頓 (英國), 博士. 大衛·謝弗 (美國), 博士. 基爾斯滕都沉浸式 (挪威), 總理斯蒂芬·SPAHN (美國), 伊夫Theze (法國公立高中美國), 查爾斯Ungerleider教授 (加拿大), 托尼·瓦格納教授 (美國), 大衛·沃森爵士 (英國), 迪倫Wiliam教授 (英國), 博士. 馬克沃莫爾德 (英國), 西奧Wubbels教授 (荷蘭), 邁克爾·楊教授 (英國), 和張民選教授 (中國) 因為他們探索所有國家今天面臨的大畫面的教育問題. 全球搜索教育社區頁面
ç. M. 魯賓是兩個廣為傳誦的在線系列，她接受了筆者 2011 厄普頓·辛克萊獎, “全球搜索教育” 和 “我們將如何閱讀?” 她也是三本暢銷書, 其中 真正的愛麗絲夢遊仙境.
最新評論